Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2019
Pharmacy Choice - Pharmaceutical News - Adial Pharmaceuticals to Present at The 2019 Wall Street Conference [Sudan Tribune] - January 20, 2019

Pharmacy News Article

 1/11/19 - Adial Pharmaceuticals to Present at The 2019 Wall Street Conference [Sudan Tribune]

(GlobeNewswire) - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that William Stilley, President and Chief Executive Officer of Adial, will be presenting at the 2019 Wall Street Conference (http://wallstconference.com/). The conference will be held on Wednesday, January 16th, 2019 at the Mar-a-Lago in Palm Beach, Florida and the presentation will be at 1:20 PM Eastern Standard Time.

The Wall Street Conference is one of the premiere conferences in the venture capital arena and small cap marketplace. Financial industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, attend the Wall Street Conference every year to discuss significant trends in emerging and growth industries.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Companys lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Companys proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

Contact:

Crescendo Communications, LLCDavid WaldmanTel: 212-671-1021Email: dwaldman@crescendo-ir.com



(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jan 20: An Integrative Approach to Managing Arthritis
Last Chance
Jan 21: Identifying, Targeting and Managing Chronic Renal Failure
Jan 22: Medication Use During Pregnancy & Lactation
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415